All companies › KROS

KROS · Keros Therapeutics, Inc.

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys1
Open-market sells4
Total purchased$10,270
Unique insiders buying1
Most senior buyerDirector
Avg price paid$10.27
Research cases0
Last filing2026-08-18

Average price paid is weighted by shares, so a large purchase counts for more than a small one. It is what insiders reported paying, not a target or a fair value.

Insider flow: Net selling by value — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-08-17 — BIENAIME JEAN JACQUES · bought 1,000 @ $10.27 2026-08-18 — Newton Charles W. · sold 551 @ $10.30 2026-08-18 — Lerner Lorena Raquel · sold 3,568 @ $10.29 2026-08-18 — Cho Esther · sold 4,485 @ $10.29 2026-08-18 — Tanini Annita · sold 1,224 @ $10.29
2026-08-172026-08-18

Insider cost basis

Share-weighted average price across 1 reported purchase, with the full range of prices paid. Purchases only — averaging a sale into an "insider cost" would describe a price nobody paid.

$10.27 $10.27
$10.27 weighted average insider purchase price

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

BIENAIME JEAN JACQUES Director
Newton Charles W. Director
Lerner Lorena Raquel Chief Scientific Officer
Cho Esther Chief Legal Officer
Tanini Annita Corp. Controller & VP, Finance
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $KROS is the reading of them — and for this company, that is what the list below says it is, no more.

  • Insider cost basisShare-weighted average price paid across the 1 reported purchase, with the full range, against the current price.
  • Insider participationWho bought, how often, and how the buying is distributed across the people filing — one person repeating is not several agreeing.
  • Transaction timelineThe [{'transaction_date': '2026-08-18', 'insider_name': 'Newton Charles W.', 'insider_title': 'Director', 'transaction_type': 'Open-market sell', 'shares': 551.0, 'price': 10.3, 'value': 5675.3, 'is_buy': False}, {'transaction_date': '2026-08-18', 'insider_name': 'Lerner Lorena Raquel', 'insider_title': 'Chief Scientific Officer', 'transaction_type': 'Open-market sell', 'shares': 3568.0, 'price': 10.29, 'value': 36714.72, 'is_buy': False}, {'transaction_date': '2026-08-18', 'insider_name': 'Cho Esther', 'insider_title': 'Chief Legal Officer', 'transaction_type': 'Open-market sell', 'shares': 4485.0, 'price': 10.29, 'value': 46150.65, 'is_buy': False}, {'transaction_date': '2026-08-18', 'insider_name': 'Tanini Annita', 'insider_title': 'Corp. Controller & VP, Finance', 'transaction_type': 'Open-market sell', 'shares': 1224.0, 'price': 10.29, 'value': 12594.96, 'is_buy': False}, {'transaction_date': '2026-08-17', 'insider_name': 'BIENAIME JEAN JACQUES', 'insider_title': 'Director', 'transaction_type': 'Open-market buy', 'shares': 1000.0, 'price': 10.27, 'value': 10270.0, 'is_buy': True}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for KROS today: no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.